Literature DB >> 20636397

Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases.

A V Marzano1, M Cugno, V Trevisan, D Fanoni, L Venegoni, E Berti, C Crosti.   

Abstract

Pyoderma gangrenosum (PG) is a rare, immune-mediated inflammatory skin disease presenting with painful ulcers having undermined edges. Less commonly, bullous and vegetative variants exist. Histology consists of a neutrophil-rich dermal infiltrate. We characterized immunohistochemically the infiltrate in different variants of PG and in another neutrophilic dermatosis as Sweet's syndrome. We studied 21 patients with PG, eight with Sweet's syndrome and 20 controls, evaluating skin immunoreactivity for inflammatory cell markers (CD3, CD163 and myeloperoxidase), cytokines [tumour necrosis factor (TNF)-α, interleukin (IL)-8 and IL-17], metalloproteinases (MMP-2 and MMP-9) and vascular endothelial growth factor (VEGF). Immunoreactivities of CD3, CD163, myeloperoxidase, TNF-α, IL-8, IL-17, MMP-2, MMP-9 and VEGF were significantly higher in both PG and Sweet's syndrome than in controls (P=0·0001). Myeloperoxidase (neutrophil marker), IL-8 (cytokine chemotactic for neutrophils) and MMP-9 (proteinase-mediating tissue damage) were expressed more significantly in both ulcerative and bullous PG than in vegetative PG as well as in Sweet's syndrome (P=0·008-P=0·0001). In ulcerative PG, the expression of CD3 (panT cell marker) and CD163 (macrophage marker) were significantly higher in wound edge than wound bed (P=0·0001). In contrast, the neutrophil marker myeloperoxidase was expressed more significantly in wound bed than wound edge (P=0·0001). Our study identifies PG as a paradigm of neutrophil-mediated inflammation, with proinflammatory cytokines/chemokines and MMPs acting as important effectors for the tissue damage, particularly in ulcerative and bullous PG where damage is stronger. In ulcerative PG, the wound bed is the site of neutrophil-recruitment, whereas in the wound edge activated T lymphocytes and macrophages pave the way to ulcer formation.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20636397      PMCID: PMC2990935          DOI: 10.1111/j.1365-2249.2010.04201.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases.

Authors:  Q Gao; M J W Meijer; F J G M Kubben; C F M Sier; L Kruidenier; W van Duijn; M van den Berg; R A van Hogezand; C B H W Lamers; H W Verspaget
Journal:  Dig Liver Dis       Date:  2005-08       Impact factor: 4.088

Review 2.  Matrix metalloproteinase degradation of extracellular matrix: biological consequences.

Authors:  S D Shapiro
Journal:  Curr Opin Cell Biol       Date:  1998-10       Impact factor: 8.382

3.  Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts.

Authors:  M Oka; C Berking; M Nesbit; K Satyamoorthy; H Schaider; G Murphy; M Ichihashi; E Sauter; M Herlyn
Journal:  Lab Invest       Date:  2000-04       Impact factor: 5.662

4.  Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum.

Authors:  Angelo Valerio Marzano; Valentina Trevisan; Riccardo Lazzari; Carlo Crosti
Journal:  J Dermatolog Treat       Date:  2010-05       Impact factor: 3.359

5.  Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane.

Authors:  C Delclaux; C Delacourt; M P D'Ortho; V Boyer; C Lafuma; A Harf
Journal:  Am J Respir Cell Mol Biol       Date:  1996-03       Impact factor: 6.914

6.  IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha.

Authors:  C Albanesi; A Cavani; G Girolomoni
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

Review 7.  Properties of the novel proinflammatory supergene "intercrine" cytokine family.

Authors:  J J Oppenheim; C O Zachariae; N Mukaida; K Matsushima
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

8.  Serum interleukin-8 in inflammatory bowel disease.

Authors:  S C Jones; S W Evans; A J Lobo; M Ceska; A T Axon; J T Whicher
Journal:  J Gastroenterol Hepatol       Date:  1993 Nov-Dec       Impact factor: 4.029

9.  Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members.

Authors:  Matthew J Ruddy; Grace C Wong; Xikui K Liu; Hiroyasu Yamamoto; Soji Kasayama; Keith L Kirkwood; Sarah L Gaffen
Journal:  J Biol Chem       Date:  2003-11-04       Impact factor: 5.157

10.  Neutrophilic dermatosis of myeloproliferative disorders. Atypical forms of pyoderma gangrenosum and Sweet's syndrome associated with myeloproliferative disorders.

Authors:  W Caughman; R Stern; H Haynes
Journal:  J Am Acad Dermatol       Date:  1983-11       Impact factor: 11.527

View more
  43 in total

Review 1.  Rosacea: The cytokine and chemokine network.

Authors:  Peter Arne Gerber; Bettina Alexandra Buhren; Martin Steinhoff; Bernhard Homey
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

Review 2.  Neutrophilic dermatoses and autoinflammatory diseases with skin involvement--innate immune disorders.

Authors:  Alexander A Navarini; Takashi K Satoh; Lars E French
Journal:  Semin Immunopathol       Date:  2015-11-30       Impact factor: 9.623

Review 3.  SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment.

Authors:  Davide Firinu; Vanessa Garcia-Larsen; Paolo Emilio Manconi; Stefano R Del Giacco
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

4.  Broadening the translational immunology landscape.

Authors:  M Peakman
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

5.  Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort Study.

Authors:  Adam V Weizman; Brian Huang; Stephan Targan; Marla Dubinsky; Phillip Fleshner; Manreet Kaur; Andrew Ippoliti; Deepa Panikkath; Eric Vasiliauskas; David Shih; Dermot P B McGovern; Gil Y Melmed
Journal:  J Cutan Med Surg       Date:  2014-10       Impact factor: 2.092

6.  Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome.

Authors:  A V Marzano; D Fanoni; E Antiga; P Quaglino; M Caproni; C Crosti; P L Meroni; M Cugno
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 7.  [Pyoderma gangrenosum].

Authors:  K Herberger
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

8.  T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum.

Authors:  E Antiga; R Maglie; W Volpi; B Bianchi; E Berti; A V Marzano; M Caproni
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

Review 9.  Pyoderma gangrenosum-like ulcerations in granulomatosis with polyangiitis: two cases and literature review.

Authors:  Giovanni Genovese; Simona Tavecchio; Emilio Berti; Franco Rongioletti; Angelo Valerio Marzano
Journal:  Rheumatol Int       Date:  2018-05-02       Impact factor: 2.631

Review 10.  Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria.

Authors:  Angelo V Marzano; Rim S Ishak; Simone Saibeni; Carlo Crosti; Pier Luigi Meroni; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.